AR and lung cancer: The previously designed small peptide AEYLR (AR) could specifically recognize the over-expressed epidermal growth factor receptor (EGFR) on the lung cancer cell membrane, AR conjugated nanostructured lipid carriers (NLC) was also proved to target the EGFR overexpressed cells and increase the drug accumulation inside the cancer cells (Han et al., 2013, 2014).